<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345696</url>
  </required_header>
  <id_info>
    <org_study_id>XELOXAVBISEMANAL</org_study_id>
    <nct_id>NCT00345696</nct_id>
  </id_info>
  <brief_title>1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&amp;Bevacizumab Every 2weeks in Metastatic CCR.</brief_title>
  <official_title>Phase II Study of First Line Capecitabine Administered on Continuous Way Combined With Oxaliplatin and Bevacizumab Every Two Weeks in Metastatic Colorectal Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unidad Integral de Investigación en Oncología S.L.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Unidad Integral de Investigación en Oncología S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determinate progression free survival after 9 months of&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To look for a new chemotherapy management to get less acute and chronic toxicity and/or an&#xD;
      easier administration treatment line.&#xD;
&#xD;
      This study tries to demonstrate an alternative chemotherapy scheme,continuous&#xD;
      polychemotherapy regimen with less dose with the added effect of the monoclonal antibody&#xD;
      Bevacizumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response rate</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of the combination of capecitabine+oxaliplatin+bevacizumab</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resection rate of hepatic or pulmonary metastases</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">32</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5 mg/Kg intravenous, 90-60-30 minutes, every 2 weeks.</description>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>600 mg/m2, orally, every 12 hours, continuous.</description>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatine</intervention_name>
    <description>85 mg/m2, intravenous, 2 hours infusion, every 2 weeks</description>
    <other_name>Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women &gt; or = 18 years&#xD;
&#xD;
          -  Outpatients with ECOG performance status ≤ 2.&#xD;
&#xD;
          -  Histologically confirmed diagnosis of CRC patients with metastasis.&#xD;
&#xD;
          -  Presence of at least one detectable lesion in accordance with RECIST criteria.&#xD;
&#xD;
          -  Life expectancy greater than 3 months.&#xD;
&#xD;
          -  Patients who are able to understand the study request and want to participate.&#xD;
&#xD;
          -  Written informed consent given&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have been treated with Bevacizumab previously.&#xD;
&#xD;
          -  Received any systemic treatment previously to treat an advanced or metastatic disease&#xD;
&#xD;
          -  Adjuvant or neoadjuvant treatment to non-metastatic disease is allowed, provided that&#xD;
             there has been finished at least 6 months before the initial study treatment.&#xD;
&#xD;
          -  If the patient has been treated with adjuvant therapy previously, it is not allowed to&#xD;
             be included in the study in case of disease progression during the treatment or during&#xD;
             6 months later than the end of the treatment.&#xD;
&#xD;
          -  If radiotherapy has been administered it has not been administered in the lesion&#xD;
             selected for the study, and the end of the treatment has been finished at least 4&#xD;
             weeks before the study initiation.&#xD;
&#xD;
          -  Previous surgical procedure of the IV stage disease is allowed.&#xD;
&#xD;
          -  PAst or current history (within the last 5 years) of malignancies except curatively&#xD;
             treated basal and squamous cell carcinoma of the skin, and in-situ carcinoma of the&#xD;
             cervix.&#xD;
&#xD;
          -  History or evidence upon physical examination of central nervous system (CNS) (i.e.&#xD;
             primary cerebral tumour, uncontrolled convulsions with standard medical treatment,&#xD;
             cerebral metastasis or any kind or ictus history).&#xD;
&#xD;
          -  History of psychiatric disability judged by the investigator to be clinically&#xD;
             significant precluding informed consent or interfering with compliance for oral drug&#xD;
             intake.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease (active), i.e, uncontrolled&#xD;
             hypertension, unstable angina, New York Heart Association (NYHA) grade II or greater&#xD;
             congestive heart failure, serious cardiac arrhythmia requiring medication or&#xD;
             peripheral vascular disease. Patients have undergone myocardial infarction in the&#xD;
             previous year of the study initiation will be excluded.&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome&#xD;
             or inability to take oral medications&#xD;
&#xD;
          -  Patients subjected to allogenic transplant and request immunotherapy.&#xD;
&#xD;
          -  Bone fracture not healed, wounds or severe ulcers.&#xD;
&#xD;
          -  Known hemorrhagic diathesis or coagulopathy.&#xD;
&#xD;
          -  Uncontrolled and severe intercurrent infections or another severe and uncontrolled&#xD;
             concomitant diseases.&#xD;
&#xD;
          -  Moderate or severe renal impairment (creatinine clearance &lt; 30 ml/min (calculated&#xD;
             according to Cockroft-Gault formula) or serum creatinine &gt;1,5 x ULN.&#xD;
&#xD;
          -  Any of the following laboratory values:&#xD;
&#xD;
        Absolute neutrophils count (ANC) &lt; 1.5 x 109/l. Platelet count &lt; 100 x 109/l. Hemoglobin &lt;&#xD;
        9 g/dl. INR &gt; 1.5. Total bilirubin &gt; 1.5 ULN. ALT and/or AST &gt; 2.5 x ULN or &gt; 5 x ULN (in&#xD;
        case of hepatic metastasis). Alkaline phosphatase &gt; 2.5 x ULN or &gt;5 x ULN (in case of&#xD;
        hepatic metastasis), or &gt; 10 x ULN (in case of bone metastasis).&#xD;
&#xD;
          -  History of unexpected serious adverse events to fluoropyrimidine treatments or known&#xD;
             dihydropyrimidine dehydrogenase (DPD) deficiency.&#xD;
&#xD;
          -  Patients subjected to major surgical procedure, open biopsy or who had significant&#xD;
             traumatic injures in 28 days time before the start of the study treatment , or&#xD;
             patients with a major surgery procedure planning during the study period. Fine needle&#xD;
             aspiration biopsy 7 days before the study initiation.&#xD;
&#xD;
          -  Use of full dose of oral or parenteral anticoagulants ( at least 10 days before the&#xD;
             start of the study treatment or thrombolytic agents. Low dose of warfarin is allowed,&#xD;
             with an INR ≤ 1.5.&#xD;
&#xD;
          -  Subject requiring chronic use of high dose aspirin (&gt; 325 m/day) or non-steroidal&#xD;
             anti-inflammatory treatment.&#xD;
&#xD;
          -  Participation in another treatment trial within 4 weeks of the study initiation.&#xD;
&#xD;
          -  Pregnant (serum positive pregnancy test) or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Grávalos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Unidad Integral de Investigación en Oncología S.L.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Grávalos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital 12 de Octubre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>June 27, 2006</study_first_submitted>
  <study_first_submitted_qc>June 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2006</study_first_posted>
  <last_update_submitted>August 23, 2011</last_update_submitted>
  <last_update_submitted_qc>August 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Capecitabine</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>First line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

